Vivo Capital Fund VIII, L.P. 4

Accession 0001213900-21-023652

CIK 0001445499other

View on SEC.gov Company Profile

Filed

Apr 28, 8:00 PM ET

Accepted

Apr 29, 9:10 PM ET

Size

51.2 KB

Accession

0001213900-21-023652

Insider Transaction Report

Form 4

Period: 2021-04-27

IMPEL NEUROPHARMA INCIMPL

Vivo Capital VIII, LLC

10% Owner

Transactions

Conversion
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−1,073,308→ 0 total(indirect: See footnote)
→ Common Stock (65,552 underlying)
Conversion
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27−995,714→ 0 total(indirect: See footnote)
→ Common Stock (60,813 underlying)
Conversion
Common Stock
2021-04-27+710,190→ 710,190 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+474,713→ 1,184,903 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+60,813→ 224,433 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+315,328→ 1,940,350 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+43,550→ 267,983 total(indirect: See footnote)
Conversion
5% Convertible Note due 2021
2021-04-27→ 0 total(indirect: See footnote)
Exercise: $13.50Exp: 2021-12-31→ Common Stock (89,145 underlying)
Conversion
Common Stock
2021-04-27+440,119→ 1,625,022 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27$13.50/sh+12,311$166,199→ 280,294 total(indirect: See footnote)
Purchase
Common Stock
2021-04-27$15.00/sh+69,380$1,040,700→ 349,674 total(indirect: See footnote)
Conversion
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−11,628,174→ 0 total(indirect: See footnote)
→ Common Stock (710,190 underlying)
Conversion
Common Stock
2021-04-27$13.50/sh+89,145$1,203,458→ 2,029,495 total(indirect: See footnote)
Purchase
Common Stock
2021-04-27$15.00/sh+505,620$7,584,300→ 2,535,115 total(indirect: See footnote)
Conversion
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−1,605,711→ 0 total(indirect: See footnote)
→ Common Stock (98,068 underlying)
Conversion
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27−7,206,216→ 0 total(indirect: See footnote)
→ Common Stock (440,119 underlying)
Conversion
Series D Redeemable Convertible Preferred Stock
2021-04-27−5,162,969→ 0 total(indirect: See footnote)
→ Common Stock (315,328 underlying)
Conversion
Common Stock
2021-04-27+98,068→ 98,068 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+65,552→ 163,620 total(indirect: See footnote)
Conversion
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−7,772,634→ 0 total(indirect: See footnote)
→ Common Stock (474,713 underlying)
Conversion
Series D Redeemable Convertible Preferred Stock
2021-04-27−713,064→ 0 total(indirect: See footnote)
→ Common Stock (43,550 underlying)
Conversion
5% Convertible Note due 2021
2021-04-27→ 0 total(indirect: See footnote)
Exercise: $13.50Exp: 2021-12-31→ Common Stock (12,311 underlying)

Vivo Capital Fund VIII, L.P.

10% Owner

Transactions

Conversion
Common Stock
2021-04-27+474,713→ 1,184,903 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+440,119→ 1,625,022 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+315,328→ 1,940,350 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+710,190→ 710,190 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+98,068→ 98,068 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+65,552→ 163,620 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+60,813→ 224,433 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+43,550→ 267,983 total(indirect: See footnote)
Conversion
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−1,605,711→ 0 total(indirect: See footnote)
→ Common Stock (98,068 underlying)
Conversion
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27−7,206,216→ 0 total(indirect: See footnote)
→ Common Stock (440,119 underlying)
Conversion
Series D Redeemable Convertible Preferred Stock
2021-04-27−5,162,969→ 0 total(indirect: See footnote)
→ Common Stock (315,328 underlying)
Conversion
Series D Redeemable Convertible Preferred Stock
2021-04-27−713,064→ 0 total(indirect: See footnote)
→ Common Stock (43,550 underlying)
Conversion
Common Stock
2021-04-27$13.50/sh+12,311$166,199→ 280,294 total(indirect: See footnote)
Conversion
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−11,628,174→ 0 total(indirect: See footnote)
→ Common Stock (710,190 underlying)
Conversion
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−1,073,308→ 0 total(indirect: See footnote)
→ Common Stock (65,552 underlying)
Purchase
Common Stock
2021-04-27$15.00/sh+505,620$7,584,300→ 2,535,115 total(indirect: See footnote)
Purchase
Common Stock
2021-04-27$15.00/sh+69,380$1,040,700→ 349,674 total(indirect: See footnote)
Conversion
5% Convertible Note due 2021
2021-04-27→ 0 total(indirect: See footnote)
Exercise: $13.50Exp: 2021-12-31→ Common Stock (12,311 underlying)
Conversion
Common Stock
2021-04-27$13.50/sh+89,145$1,203,458→ 2,029,495 total(indirect: See footnote)
Conversion
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−7,772,634→ 0 total(indirect: See footnote)
→ Common Stock (474,713 underlying)
Conversion
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27−995,714→ 0 total(indirect: See footnote)
→ Common Stock (60,813 underlying)
Conversion
5% Convertible Note due 2021
2021-04-27→ 0 total(indirect: See footnote)
Exercise: $13.50Exp: 2021-12-31→ Common Stock (89,145 underlying)

Vivo Capital Surplus Fund VIII, L.P.

10% Owner

Transactions

Conversion
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−11,628,174→ 0 total(indirect: See footnote)
→ Common Stock (710,190 underlying)
Conversion
Common Stock
2021-04-27+710,190→ 710,190 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+65,552→ 163,620 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+60,813→ 224,433 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+315,328→ 1,940,350 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27$13.50/sh+89,145$1,203,458→ 2,029,495 total(indirect: See footnote)
Purchase
Common Stock
2021-04-27$15.00/sh+505,620$7,584,300→ 2,535,115 total(indirect: See footnote)
Conversion
Series C-1 Redeemable Convertible Preferred Stock
2021-04-27−1,605,711→ 0 total(indirect: See footnote)
→ Common Stock (98,068 underlying)
Conversion
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−1,073,308→ 0 total(indirect: See footnote)
→ Common Stock (65,552 underlying)
Conversion
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27−995,714→ 0 total(indirect: See footnote)
→ Common Stock (60,813 underlying)
Conversion
Series D Redeemable Convertible Preferred Stock
2021-04-27−713,064→ 0 total(indirect: See footnote)
→ Common Stock (43,550 underlying)
Conversion
5% Convertible Note due 2021
2021-04-27→ 0 total(indirect: See footnote)
Exercise: $13.50Exp: 2021-12-31→ Common Stock (89,145 underlying)
Conversion
5% Convertible Note due 2021
2021-04-27→ 0 total(indirect: See footnote)
Exercise: $13.50Exp: 2021-12-31→ Common Stock (12,311 underlying)
Conversion
Common Stock
2021-04-27+98,068→ 98,068 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+474,713→ 1,184,903 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+440,119→ 1,625,022 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27+43,550→ 267,983 total(indirect: See footnote)
Conversion
Common Stock
2021-04-27$13.50/sh+12,311$166,199→ 280,294 total(indirect: See footnote)
Purchase
Common Stock
2021-04-27$15.00/sh+69,380$1,040,700→ 349,674 total(indirect: See footnote)
Conversion
Series C-2 Redeemable Convertible Preferred Stock
2021-04-27−7,772,634→ 0 total(indirect: See footnote)
→ Common Stock (474,713 underlying)
Conversion
Series C-3 Redeemable Convertible Preferred Stock
2021-04-27−7,206,216→ 0 total(indirect: See footnote)
→ Common Stock (440,119 underlying)
Conversion
Series D Redeemable Convertible Preferred Stock
2021-04-27−5,162,969→ 0 total(indirect: See footnote)
→ Common Stock (315,328 underlying)

Footnotes (4)

[F1]Each share of Series C-1, C-2, C-3 and D Redeemable Convertible Preferred Stock is automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one share of common stock for 16.37332 preferred shares basis.
[F2]The convertible promissory note was issued by the issuer on March 5, 2021 and the outstanding principal and accrued interest is automatically converted into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering at $13.50 per share (90% of the IPO price).
[F3]The securities reported herein are held of record by Vivo Capital Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.
[F4]The securities reported herein are held of record by Vivo Capital Surplus Fund VIII, L.P. Vivo Capital VIII, LLC is the general partner of Vivo Capital Surplus Fund VIII, L.P. As the managing members of Vivo Capital VIII, LLC, Frank Kung, Edgar Engleman and Shan Fu share voting and dispositive power over the shares held by Vivo Capital Surplus Fund VIII, L.P., but each disclaims beneficial ownership of such shares except to the extent of their individual pecuniary interest therein.

Documents

1 file

4
ownership.xmlPrimary

Issuer

IMPEL NEUROPHARMA INC

CIK 0001445499

→

Entity typeother

Related Parties

filerCIK 0001618788

Filing Metadata

Form type: 4
Filed: Apr 28, 8:00 PM ET
Accepted: Apr 29, 9:10 PM ET
Size: 51.2 KB

View on SEC.gov